Sanofi Genzyme
Sanofi Genzyme is a pharmaceutical company and its products and services are focused on areas such as rare inherited disorders, kidney disease, cancer, transplant and immune disease.
Established in 2001, Genzyme Waterford is situated on a 37-acre site in Waterford. This multi-phased biopharmaceutical facility has seen capital investment of over €500 million.
It is a state-of-the-art facility that serves patients across more than 70 countries. Additional products continue to be developed and introduced to the site with the current expansion set to bring the first Sanofi insulin products to the facility.
Since Sanofi’s acquisition of Genzyme in 2011, the Waterford site has become more closely aligned with the Sanofi network in Europe .
Financial Data
-
31st Dec 17 Source: CRO
- €981.7 million turnover
-
€272.6 million
profit - 615 employees
-
31st Dec 16 Source: CRO
- €1.3 billion turnover
-
€99.5 million
profit - 588 employees
- 10 more years available »
Ranking
By Turnover
(€981.7 million)- 83rd in Top Companies
- 12th in Pharma
By Employees
(615)- 304th in Top Companies
- 26th in Pharma
-
- 615
- €981.7 million
Employees
- Ruth Beadle General Manager
Latest News
- 7:34pm Pay dispute threatens to disrupt North’s electricity supply
- 6:37pm Shares slide as Brexit and US data stoke fears of a slow down
- 6:37pm Values slide as Brexit and US data stoke fears of slowdown
- 5:53pm Red Cow Moran Hotel sees book value more than double to €48.5m
- 5:00pm Netflix reinvents itself: ‘We’re really mostly a content company’